{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T02:12:18Z","timestamp":1792289538403,"version":"4.4.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,1,10]],"date-time":"2014-01-10T00:00:00Z","timestamp":1389312000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2014,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Rifampicin resistance is a risk factor for poor outcome in tuberculosis. Therefore, we sought to describe the characteristics and management of Rifampicin monoresistant (RMR) tuberculosis (TB) in France.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We conducted a retrospective cohort analysis in 2012 on RMR TB patients diagnosed in France between 2005 and 2010 by using a national laboratory network. A standardized questionnaire was used to collect basic demographic data, region of birth, history of TB, HIV-coinfection, alcohol use, and antituberculosis treatment. Outcome was assessed after at least 18 months of follow-up.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>A total of 39 patients with RMR TB were reported (0.12% of all TB cases). Overall, 19 (49%) had a previous history of treatment, 9 (23%) were HIV-coinfected, and 24 (62%) were smear-positive. Patient with secondary RMR were more likely to have alcohol abuse (P\u2009=\u20090.04) and HIV-coinfection (p\u2009=\u20090.04). Treatment outcome could be assessed for 30 patients, the nine others being dead or lost to follow-up. A total of 20 (67%) of the 30 assessed were cured, 3 (10%) died, 3 (10%) relapsed, and 4 (13%) were lost to follow up. Four (13%) received less than 6 months of treatment, 3 did not have any modification of the standardized regimen, 13 (43%) received fluoroquinolones, 4 (13%) aminoglycosides, and 8 (26%) a combination of both.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>RMR TB is a rare disease in France, and its management was heterogeneous. The lack of treatment standardization may be a consequence of low expertise and may lead to the unsatisfactory low success rate.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1471-2334-14-18","type":"journal-article","created":{"date-parts":[[2014,1,10]],"date-time":"2014-01-10T17:00:47Z","timestamp":1389373247000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Rifampicin mono-resistant tuberculosis in France: a 2005\u20132010 retrospective cohort analysis"],"prefix":"10.1186","volume":"14","author":[{"given":"Vanina","family":"Meyssonnier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thuy Van","family":"Bui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Veziris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Jarlier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"Robert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,1,10]]},"reference":[{"key":"2977_CR1","unstructured":"World Health Organization: Global tuberculosis report 2013. http:\/\/www.who.int\/tb\/publications\/global_report\/en\/,"},{"key":"2977_CR2","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1164\/ajrccm.161.4.16141","volume":"161","author":"American Thoracic Society, Centers for Disease Control and Prevention","year":"2000","unstructured":"American Thoracic Society, Centers for Disease Control and Prevention: Diagnostic standards and classification of tuberculosis in adults and children. Am J Respir Crit Care Med. 2000, 161: 1376-1395.","journal-title":"Am J Respir Crit Care Med"},{"key":"2977_CR3","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.jinf.2012.01.013","volume":"64","author":"V Meyssonnier","year":"2012","unstructured":"Meyssonnier V, Veziris N, Bastian S, Texier-Maugein J, Jarlier V, Robert J: Increase in primary drug resistance of Mycobacterium tuberculosis in younger birth cohorts in France. J Infect. 2012, 64: 589-595.","journal-title":"J Infect"},{"key":"2977_CR4","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1164\/ajrccm.157.6.9712009","volume":"157","author":"R Ridzon","year":"1998","unstructured":"Ridzon R, Whitney CG, McKenna MT, Taylor JP, Ashkar SH, Nitta AT, et al: Risk factors for rifampin mono-resistant tuberculosis. Am J Respir Crit Care Med. 1998, 157: 1881-1884.","journal-title":"Am J Respir Crit Care Med"},{"key":"2977_CR5","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1183\/09031936.00037207","volume":"30","author":"PM Khu\u00ea","year":"2007","unstructured":"Khu\u00ea PM, Truffot-Pernot C, Texier-Maugein J, Jarlier V, Robert J: A 10-year prospective surveillance of Mycobacterium tuberculosis drug resistance in France 1995\u20132004. Eur Respir J. 2007, 30: 937-944.","journal-title":"Eur Respir J"},{"key":"2977_CR6","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1093\/cid\/cis989","volume":"56","author":"TC Porco","year":"2013","unstructured":"Porco TC, Oh P, Flood JM: Antituberculosis drug resistance acquired during treatment: an analysis of cases reported in California, 1994\u20132006. Clin Infect Dis. 2013, 56: 761-769.","journal-title":"Clin Infect Dis"},{"key":"2977_CR7","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1093\/cid\/cir406","volume":"53","author":"KR Jacobson","year":"2011","unstructured":"Jacobson KR, Theron D, Victor TC, Streicher EM, Warren RM, Murray MB: Treatment outcomes of isoniazid-resistant tuberculosis patients, Western Cape Province, South Africa. Clin Infect Dis. 2011, 53: 369-372.","journal-title":"Clin Infect Dis"},{"key":"2977_CR8","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.jinf.2010.03.017","volume":"60","author":"D Bang","year":"2010","unstructured":"Bang D, Andersen PH, Andersen AB, Thomsen V\u00d8: Isoniazid-resistant tuberculosis in Denmark: mutations, transmission and treatment outcome. J Infect. 2010, 60: 452-457. 10.1016\/j.jinf.2010.03.017","journal-title":"J Infect"},{"key":"2977_CR9","doi-asserted-by":"publisher","first-page":"e1000150","DOI":"10.1371\/journal.pmed.1000150","volume":"6","author":"D Menzies","year":"2009","unstructured":"Menzies D, Benedetti A, Paydar A, Royce S, Madhukar P, Burman W, et al: Standardized treatment of active tuberculosis in patients with previous treatment and\/or with mono-resistance to isoniazid: a systematic review and meta-analysis. PLoS Med. 2009, 6: e1000150-","journal-title":"PLoS Med"},{"key":"2977_CR10","first-page":"585","volume":"6","author":"R Singla","year":"2002","unstructured":"Singla R, Al-Sharif N, Al-Sayegh MO, Osman MM, Shaikh MA: Influence of anti-tuberculosis drug resistance on the treatment outcome of pulmonary tuberculosis patients receiving DOTS in Riyadh, Saudi Arabia. Int J Tuberc Lung Dis. 2002, 6: 585-591.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"RR-11","key":"2977_CR11","first-page":"1","volume":"52","author":"Centers for Disease Control and Prevention","year":"2003","unstructured":"Centers for Disease Control and Prevention: Treatment of tuberculosis, American thoracic society, CDC, and infectious diseases society of america. MMWR. 2003, 52 (RR-11): 1-77.","journal-title":"MMWR"},{"key":"2977_CR12","unstructured":"Guidelines for the programmatic management of drug-resistant tuberculosis - 2011 update. WHO\/HTM\/TB\/2011.6.2011: [http:\/\/www.who.int\/tb\/challenges\/mdr\/programmatic_guidelines_for_mdrtb\/en\/]"},{"key":"2977_CR13","unstructured":"Guidelines for the programmatic management of drug-resistant tuberculosis. Emergency update 2008. WHO. WHO\/HTM\/TB\/2008.402. http:\/\/whqlibdoc.who.int\/publications\/2008\/9789241547581_eng.pdf,"},{"key":"2977_CR14","volume-title":"Guidelines for the Clinical and Operational Management of drug-resistant Tuberculosis","author":"JA Caminero","year":"2013","unstructured":"Caminero JA: Guidelines for the Clinical and Operational Management of drug-resistant Tuberculosis. 2013, Paris, France: International Union Against Tuberculosis and Lung Disease, http:\/\/www.theunion.org\/what-we-do\/publications\/technical\/guidelines-for-the-clinical-and-operational-management-of-drug-resistant-tuberculosis,"},{"key":"2977_CR15","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1183\/09031936.03.00014103","volume":"22","author":"J Robert","year":"2003","unstructured":"Robert J, Trystram D, Truffot-Pernot C, Jarlier V: Multidrug-resistant tuberculosis: eight years of surveillance in France. Eur Respir J. 2003, 22: 833-837.","journal-title":"Eur Respir J"},{"key":"2977_CR16","first-page":"260","volume":"13","author":"F Brossier","year":"2009","unstructured":"Brossier F, Veziris N, Jarlier V, Sougakoff W: Performance of MTBDR plus for detecting high\/low levels of Mycobacterium tuberculosisresistance to isoniazid. Int J Tuberc Lung Dis. 2009, 13: 260-265.","journal-title":"Int J Tuberc Lung Dis"},{"key":"2977_CR17","unstructured":"Epidemiology of tuberculosis in the EU\/EEA in 2010 \u2013 monitoring the progress towards tuberculosis elimination. [http:\/\/www.eurosurveillance.org\/ViewArticle.aspx?ArticleId=20124]"},{"key":"2977_CR18","first-page":"938178","volume":"2010","author":"C Mulenga","year":"2010","unstructured":"Mulenga C, Chonde A, Bwalya IC, Kapata N, Kakungu-Simpungwe M, Docx S, et al: Low occurrence of tuberculosis drug resistance among pulmonary tuberculosis patients from an urban setting, with a long-running DOTS program in Zambia. Tuberc Res Treat. 2010, 2010: 938178-","journal-title":"Tuberc Res Treat"},{"key":"2977_CR19","doi-asserted-by":"publisher","first-page":"196","DOI":"10.5588\/ijtld.11.0116","volume":"16","author":"FK Mukinda","year":"2012","unstructured":"Mukinda FK, Theron D, Van der Spuy GD, Jacobson KR, Roscher M, Streicher EM, et al: Rise in rifampicin-monoresistant tuberculosis in Western Cape, South Africa. Int J Tuberc Lung Dis. 2012, 16: 196-202.","journal-title":"Int J Tuberc Lung Dis"},{"key":"2977_CR20","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1086\/430377","volume":"41","author":"J Li","year":"2005","unstructured":"Li J, Munsiff SS, Driver CR, Sackoff J: Relapse and acquired rifampin resistance in HIV-infected patients with tuberculosis treated with rifampin- or rifabutin-based regimens in New York City, 1997\u20132000. Clin Infect Dis. 2005, 41: 83-91.","journal-title":"Clin Infect Dis"},{"key":"2977_CR21","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1164\/ajrccm.153.2.8564140","volume":"153","author":"M Lutfey","year":"1996","unstructured":"Lutfey M, Della-Latta P, Kapur V, Palumbo LA, Gurner D, Stotzky G, et al: Independent origin of mono-rifampin-resistant Mycobacterium tuberculosis in patients with AIDS. Am J Respir Crit Care Med. 1996, 153: 837-840.","journal-title":"Am J Respir Crit Care Med"},{"key":"2977_CR22","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1164\/ajrccm.159.2.9805097","volume":"159","author":"L Sandman","year":"1999","unstructured":"Sandman L, Schluger NW, Davidow AL, Bonk S: Risk factors for rifampin-monoresistant tuberculosis: a case\u2013control study. Am J Respir Crit Care Med. 1999, 159: 468-472.","journal-title":"Am J Respir Crit Care Med"},{"key":"2977_CR23","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1086\/516146","volume":"25","author":"SS Munsiff","year":"1997","unstructured":"Munsiff SS, Joseph S, Ebrahimzadeh A, Frieden TR: Rifampin-monoresistant tuberculosis in New York City, 1993\u20131994. Clin Infect Dis. 1997, 25: 1465-1467.","journal-title":"Clin Infect Dis"},{"key":"2977_CR24","first-page":"291","volume":"24-25","author":"N Veziris","year":"2012","unstructured":"Veziris N, Jarlier V, Robert J: Resistance to anti-tuberculosis drugs in France, 2009\u20132010. Bull Epidemiol Hebdo. 2012, 24-25: 291-293.","journal-title":"Bull Epidemiol Hebdo"},{"key":"2977_CR25","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1378\/chest.09-0394","volume":"137","author":"CR Horsburgh Jr","year":"2010","unstructured":"Horsburgh CR, Goldberg S, Bethel J, Chen S, Colson PW, Hirsch-Moverman Y, et al: Latent tuberculosis infection treatment acceptance and completion in the United States and Canada. Chest. 2010, 137: 401-409.","journal-title":"Chest"},{"key":"2977_CR26","first-page":"1104","volume":"14","author":"Y Hirsch-Moverman","year":"2010","unstructured":"Hirsch-Moverman Y, Bethel J, Colson PW, Franks J, El-Sadr W: Predictors of latent tuberculosis infection treatment completion in the United States: an inner city experience. Int J Tuberc Lung Dis. 2010, 14: 1104-1111.","journal-title":"Int J Tuberc Lung Dis"},{"key":"2977_CR27","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/S0002-9343(96)00402-0","volume":"102","author":"A Pablos-M\u00e9ndez","year":"1997","unstructured":"Pablos-M\u00e9ndez A, Knirsch CA, Barr RG, Lerner BH, Frieden TR: Nonadherence in tuberculosis treatment: predictors and consequences in New York City. Am J Med. 1997, 102: 164-170.","journal-title":"Am J Med"},{"key":"2977_CR28","doi-asserted-by":"publisher","first-page":"5085","DOI":"10.1128\/AAC.00269-11","volume":"55","author":"S Srivastava","year":"2011","unstructured":"Srivastava S, Sherman C, Meek C, Leff R, Gumbo T: Pharmacokinetic mismatch does not lead to emergence of isoniazid- or rifampin-resistant Mycobacterium tuberculosis but to better antimicrobial effect: a new paradigm for antituberculosis drug scheduling. Antimicrob Agents Chemother. 2011, 55: 5085-5089.","journal-title":"Antimicrob Agents Chemother"},{"key":"2977_CR29","doi-asserted-by":"publisher","first-page":"76","DOI":"10.5588\/ijtld.11.0360","volume":"16","author":"A Dramowski","year":"2012","unstructured":"Dramowski A, Morsheimer MM, Jordaan AM, Victor TC, Donald PR, Schaaf HS: Rifampicin-monoresistant Mycobacterium tuberculosis disease among children in Cape Town, South Africa. Int J Tuberc Lung Dis. 2012, 16: 76-81.","journal-title":"Int J Tuberc Lung Dis"},{"key":"2977_CR30","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1164\/ajrccm.160.2.9901012","volume":"160","author":"M Flament-Saillour","year":"1999","unstructured":"Flament-Saillour M, Robert J, Jarlier V, Grosset J: Outcome of multi-drug-resistant tuberculosis in France: a nationwide case\u2013control study. Am J Respir Crit Care Med. 1999, 160: 587-593.","journal-title":"Am J Respir Crit Care Med"},{"key":"2977_CR31","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.ijantimicag.2006.11.023","volume":"29","author":"M-L Uffredi","year":"2007","unstructured":"Uffredi M-L, Truffot-Pernot C, Dautzenberg B, Renard M, Jarlier V, Robert J: An intervention programme for the management of multidrug-resistant tuberculosis in France. Int J Antimicrob Agents. 2007, 29: 434-439.","journal-title":"Int J Antimicrob Agents"},{"key":"2977_CR32","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1128\/AAC.01024-12","volume":"57","author":"Y Pang","year":"2013","unstructured":"Pang Y, Lu J, Wang Y, Song Y, Wang S, Zhao Y: Study of the rifampin mono-resistance mechanism in Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2013, 57: 893-900.","journal-title":"Antimicrob Agents Chemother"},{"key":"2977_CR33","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1128\/AAC.41.12.2670","volume":"41","author":"CA Peloquin","year":"1997","unstructured":"Peloquin CA, Jaresko GS, Yong CL, Keung AC, Bulpitt AE, Jelliffe RW: Population pharmacokinetic modeling of isoniazid, rifampin, and pyrazinamide. Antimicrob Agents Chemother. 1997, 41: 2670-2679.","journal-title":"Antimicrob Agents Chemother"},{"key":"2977_CR34","doi-asserted-by":"publisher","first-page":"4765","DOI":"10.1128\/AAC.00968-10","volume":"54","author":"J Poissy","year":"2010","unstructured":"Poissy J, Aubry A, Fernandez C, Lott M-C, Chauffour A, Jarlier V, et al: Should moxifloxacin be used for the treatment of extensively drug-resistant tuberculosis? An answer from a murine model. Antimicrob Agents Chemother. 2010, 54: 4765-4771.","journal-title":"Antimicrob Agents Chemother"},{"key":"2977_CR35","first-page":"979","volume":"11","author":"T T\u00f6r\u00fcn","year":"2007","unstructured":"T\u00f6r\u00fcn T, Tahao\u011flu K, Ozmen I, Sevim T, Ata\u00e7 G, Kir A, et al: The role of surgery and fluoroquinolones in the treatment of multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2007, 11: 979-985.","journal-title":"Int J Tuberc Lung Dis"},{"key":"2977_CR36","doi-asserted-by":"publisher","first-page":"e1001300","DOI":"10.1371\/journal.pmed.1001300","volume":"9","author":"SD Ahuja","year":"2012","unstructured":"Ahuja SD, Ashkin D, Avendano M, Banerjee R, Bauer M, Bayona JN, et al: Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients. PLoS Med. 2012, 9: e1001300-","journal-title":"PLoS Med"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2334-14-18.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2334-14-18\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2334-14-18","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2334-14-18.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T02:45:14Z","timestamp":1630550714000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/1471-2334-14-18"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1,10]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["2977"],"URL":"https:\/\/doi.org\/10.1186\/1471-2334-14-18","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,1,10]]},"assertion":[{"value":"22 July 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2014","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2014","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"18"}}